Buscar
Genmab A/S
GMABAñadir a la lista de seguimiento
28.870USD
+0.230+0.80%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
17.79BCap. mercado
21.75P/E TTM
Más Datos de Genmab A/S Compañía
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Información de Genmab A/S
Símbolo de cotizaciónGMAB
Nombre de la empresaGenmab A/S
Fecha de salida a bolsaOct 01, 2000
Director ejecutivoVan De Winkel (Jan G.J)
Número de empleados2682
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 01
DirecciónCarl Jacobsens Vej 30
CiudadVALBY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísDenmark
Código postal2500
Teléfono4570202728
Sitio Webhttps://www.genmab.com/
Símbolo de cotizaciónGMAB
Fecha de salida a bolsaOct 01, 2000
Director ejecutivoVan De Winkel (Jan G.J)
Ejecutivos de Genmab A/S
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Mr. Rolf K. Hoffmann
Mr. Rolf K. Hoffmann
Independent Director
Independent Director
--
--
Ms. Deirdre P. Connelly
Ms. Deirdre P. Connelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Genmab A/S?
Los cinco principales accionistas de Genmab A/S son: Dr. Jan G.J. Van De Winkel, Ph.D.
¿Cuántas instituciones poseen acciones de Genmab A/S (GMAB)?
A fecha de 2026Q1, 564 instituciones poseen acciones de Genmab A/S, con un valor de mercado combinado de aproximadamente 74.31M, lo que representa el 12.10% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2989185.00.
¿Cuál es la mayor fuente de ganancias de Genmab A/S?
El 2026Q1, el segmento empresarial Royalties generó la ganancia más alta para Genmab A/S, ascendiendo a 3.10B y representando el 83.39% de la ganancia total.